Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.49
+0.7%
$243.15
$160.86
$282.15
$15.81B0.37709,615 shs143,416 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.43
+0.8%
$71.46
$42.09
$93.42
$15.95B0.953.10 million shs267,573 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.53
+1.5%
$23.70
$13.39
$27.72
$12.74B1.685.29 million shs1.01 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$28.94
+5.1%
$26.74
$5.77
$34.39
$4.18B1.123.67 million shs426,698 shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-3.54%-5.08%+9.07%+4.77%+48.18%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.76%-2.79%+21.87%+6.01%+73.64%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.58%+0.20%+3.99%+11.16%+70.33%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-3.57%-2.89%-1.54%-0.83%+306.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.49
+0.7%
$243.15
$160.86
$282.15
$15.81B0.37709,615 shs143,416 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.43
+0.8%
$71.46
$42.09
$93.42
$15.95B0.953.10 million shs267,573 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.53
+1.5%
$23.70
$13.39
$27.72
$12.74B1.685.29 million shs1.01 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$28.94
+5.1%
$26.74
$5.77
$34.39
$4.18B1.123.67 million shs426,698 shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-3.54%-5.08%+9.07%+4.77%+48.18%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-0.76%-2.79%+21.87%+6.01%+73.64%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-2.58%+0.20%+3.99%+11.16%+70.33%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-3.57%-2.89%-1.54%-0.83%+306.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$295.6717.44% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$95.2117.89% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$28.5513.39% Upside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
2.75
Moderate Buy$42.1553.06% Upside

Current Analyst Ratings Breakdown

Latest TNGX, ASND, BBIO, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Boost Price TargetOutperform$36.00 ➝ $40.00
7/16/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetNeutral$82.00 ➝ $93.00
7/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UpgradeSell (D)Hold (C)
7/15/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Initiated CoverageOverweight$46.00
7/13/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Boost Price TargetBuy$110.00 ➝ $120.00
7/7/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Boost Price TargetOutperform$275.00 ➝ $280.00
6/29/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
DowngradeSell (D-)Sell (E+)
6/29/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Reiterated RatingOverweight
6/29/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
Boost Price TargetBuy$42.00 ➝ $46.00
6/25/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
UpgradeHoldBuy$27.00 ➝ $60.00
6/25/2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
DowngradeHold
(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$865.78M18.14N/AN/A($2.97) per share-84.77
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M31.50N/AN/A($10.77) per share-7.50
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.67$2.26 per share11.13$13.18 per share1.91
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$62.38M63.86N/AN/A$2.57 per share10.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$8.6729.0420.74N/A57.87%N/A-8.37%8/6/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.74N/A897.33N/A-124.42%N/A-65.81%8/4/2026 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.50N/A20.301.69-4.95%7.42%3.66%8/5/2026 (Estimated)
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.59M-$0.83N/AN/AN/AN/A-41.54%-33.44%8/4/2026 (Estimated)

Latest TNGX, ASND, BBIO, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.27N/AN/AN/A$438.30 millionN/A
8/5/2026Q2 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.27N/AN/AN/A$1.31 billionN/A
8/4/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5836N/AN/AN/A$220.52 millionN/A
8/4/2026Q2 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.31N/AN/AN/A$1.56 millionN/A
5/13/2026Q1 2026
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.32-$0.32N/A-$0.32$0.58 millionN/A
5/7/2026Q1 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$0.21$0.32+$0.11$11.29$362.47 million$285.45 million
5/7/2026Q1 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.79
1.00
0.72
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.52
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.16
1.12
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
27.38
27.38

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.86 million167.99 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400499.45 million493.76 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
90144.65 million135.25 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$253.48 +1.73 (+0.69%)
As of 11:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$81.43 +0.67 (+0.83%)
As of 11:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$25.53 +0.39 (+1.54%)
As of 11:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$28.94 +1.40 (+5.10%)
As of 11:21 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.